Journey West: How One Small Chinese Firm Is Taking On The World
Global Place For Affordable AMD Option?
When it kicked off a pivotal study in 32 countries, a small Chengdu-based company stepped into unknown waters littered with challenges, ranging from lack of expertise to limited enthusiasm for a made in China new drug, from controls over foreign currency outflows to vetting investigators in foreign lands. But a strong early performance at home has given Kanghong confidence to take on big pharma and the world.
You may also be interested in...
China Rings In New Year With Major Deals, Record IPOs And Trends To Watch
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.
Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage
Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. In this case study, Scrip takes a deep dive into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations.
China Micron Ban Not Cause For Further Health Sector Worry?
China has taken a new counterstrike against the US in the chips sector, but the risk of potential wider impact on the biopharma sector appears to be limited given other tighter regulations already in place.